BioCentury
ARTICLE | Company News

Axovant reboots with gene therapy deal

June 6, 2018 2:00 PM UTC

Months after a clinical failure in Alzheimer's disease destroyed most of its value, Axovant Sciences Ltd. (NASDAQ:AXON) is seeking a path forward by obtaining rights to a gene therapy for Parkinson's disease.

Oxford BioMedica plc (LSE:OXB) granted Axovant exclusive, worldwide rights to OXB-102, its lentiviral gene therapy designed to stimulate dopamine production in the putamen. Axovant, which renamed the program AXO-Lenti-PD, intends to start a Phase I/II dose-escalation study of the therapy by YE18 in patients with advanced PD...